Almotriptan: a review of 20 years’ clinical experience

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976.
   PubMed Web of Science ®Google Scholar
• Vo P, Fang J, Bilitou A, et al. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19(1):82.
   PubMed Web of Science ®Google Scholar
• Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264(9):2031–2039.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. European federation of neurological societies. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981.
   PubMed Web of Science ®Google Scholar
• Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–235.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Valade D, Geraud G, et al. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain. 2014;15:2.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Davenport WJ, Marmura MJ, et al. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache. 2016;56(7):1194–1200.
   PubMed Web of Science ®Google Scholar
• Pascual J, Vila C, McGown CC. Almotriptan: a review of 10 years’ clinical experience. Expert Rev Neurother. 2010;10:1505–1517.
   PubMed Web of Science ®Google Scholar
• Gras J, Llenas J, Jansat JM, et al. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 2002;8(3):217–234.
   PubMedGoogle Scholar
• Tepper SJ, Rapport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084–1088.
   PubMedGoogle Scholar
• Jansat JM, Martinez-Tobed A, Garcia E, et al. Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. Int J Clin Pharmacol Ther. 2006;44(4):185–190.
   PubMed Web of Science ®Google Scholar
• Jansat JM, Costa J, Salvà P, et al. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol. 2002;42(12):1303–1310.
   PubMed Web of Science ®Google Scholar
• Pascual J, Muñoz P. Correlation between lipophilicity and triptan outcomes. Headache. 2005;45(1):3–6.
   PubMed Web of Science ®Google Scholar
• McEwen J, Salva M, Jansat JM, et al. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. Biopharm Drug Dispos. 2004;25(7):303–311.
   PubMed Web of Science ®Google Scholar
• McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237–246.
   PubMed Web of Science ®Google Scholar
• Salva M, Jansat JM, Martinez-Tobed A, et al. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003;31(4):404–411.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000;67(5):498–503.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol. 2001;41(2):217–223.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001;51(5):437–441.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001;21(1):61–65.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol. 2003;43(4):423–427.
   PubMed Web of Science ®Google Scholar
• Cabarrocas X, Salva M, Pavesi M, et al. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. Int J Clin Pharmacol Ther. 2006;44:443–448.
   PubMed Web of Science ®Google Scholar
• Baldwin JR, Fleishaker JC, Azie NE, et al. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia. 2004;24:288–292.
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large randomized, double-blind placebo controlled study. Cephalalgia. 2000;20:588–596.
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Tfelt-Hansen P, Massiou H, et al. Almotriptan study group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology. 2001;57:1811–1817.
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22(6):453–461.
   PubMed Web of Science ®Google Scholar
• Spierings EL. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized parallel-group, optimum-dose comparison. Arch Neurol. 2001;58(6):944–950.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007;115(1):34–40.
   PubMed Web of Science ®Google Scholar
• Láinez MJ, Galván J, Heras J, et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol. 2007;14(3):269–275.
   PubMed Web of Science ®Google Scholar
• Dahlöf CG, Pascual J, Dodick DW, et al. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia. 2006;26:400–408.
   PubMed Web of Science ®Google Scholar
• Dahlöf CG. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache. 2002;42:99–113.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21(1):73–82.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–267.
   PubMed Web of Science ®Google Scholar
• Xu H, Han W, Wang J, et al. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):113.
   PubMed Web of Science ®Google Scholar
• Evers S, Savi L, Omboni S, et al. Efficacy of frovatriptan as compared to other triptans in migraine with aura. J Headache Pain. 2015;16:514.
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol. 2001;45(4):206–213.
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002;42(1):28–31.
   PubMed Web of Science ®Google Scholar
• Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache. 2003;43(10):1075–1079.
   PubMed Web of Science ®Google Scholar
• Mathew NT. A long-term, open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache. 2002;42(1):32–40.
   Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, et al. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache. 2004;44(4):318–322.
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg time versus intensity migraine study (AIMS). Headache. 2007;47(10):519–530.
   PubMedGoogle Scholar
• Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® early migraine intervention study). Headache. 2007;47(2):189–198.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The ‘Act when mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008;28(Suppl. 2):36–41.
   PubMedGoogle Scholar
• Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain. 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• Freitag FG, Smith T, Mathew N, et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache. 2008;48:341–354.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-‘Act when mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28:383–391.
   PubMed Web of Science ®Google Scholar
• Pascual J, Diener HC, Massiou H. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain. 2006;7(1):27–33.
   PubMedGoogle Scholar
• Pascual J, Láinez JM, Leira R, et al. Grupo de Estudio TEA 2000. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologia 2003;18(1):7–17.
   PubMed Web of Science ®Google Scholar
• Tranche Iparraguirre S, Martínez Eizaguirre JM, Galván Cervera J, Grupo de Estudio TEA 2001. Tolerance to almotriptan and its effectiveness in primary care. Aten Primaria. 2005;35:52–53.
   PubMedGoogle Scholar
• Diener HC. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache. 2005;45:624–631.
   PubMed Web of Science ®Google Scholar
• Massiou H, Pradalier A, Donnet A, et al. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine–satisfaction with treatment: reality with Almogran study. Eur Neurol. 2006;55(4):198–203.
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Diaz-Insa S, Leone M, et al. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract. 2010;64(7):936–943.
   PubMed Web of Science ®Google Scholar
• Díaz-Insa S, Vila C, McGown CC. Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study. Curr Med Res Opin. 2011;27:559–567.
   PubMed Web of Science ®Google Scholar
• Leone M, Vila C, McGown C. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. Expert Rev Neurother. 2010;10(9):1399–1408.
   PubMed Web of Science ®Google Scholar
• Pascual J, Diener HC. Use of almotriptan in triptan-experienced and triptan-naïve patients. Curr Med Res Opin. 2007;23(10):2433–2440.
   PubMed Web of Science ®Google Scholar
• Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache. 2005;45(7):874–882.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Munjal S, Buse DC, et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American migraine prevalence and prevention study. Headache. 2017;57(7):1026–1040.
   PubMed Web of Science ®Google Scholar
• Schoenen J, De Klippel N, Giurgea S, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia. 2007;28(10):1095–1105.
   Web of Science ®Google Scholar
• Cady RK, Freitag FG, Mathew NT, et al. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache. 2009;49:350–363.
   PubMed Web of Science ®Google Scholar
• Díaz-Insa S, Goadsby PJ, Zanchin G, et al. The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the “Act when mild” study. Int J Neurosci. 2011;121:655–661.
   PubMed Web of Science ®Google Scholar
• Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4:CD005220.
   PubMedGoogle Scholar
• Charles JA. Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open-label pilot study of efficacy and safety. J Headache Pain. 2006;7:95–97.
   PubMedGoogle Scholar
• Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48(9):1326–1336.
   PubMed Web of Science ®Google Scholar
• Berenson F, Vasconcellos E, Pakalnis A, et al. Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents. Headache. 2010;50:795–807.
   PubMed Web of Science ®Google Scholar
• Wöber C, Brannath W, Schmidt K, et al. PAMINA Study Group. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia 2007;27(4):304–314.
   PubMed Web of Science ®Google Scholar
• Bussone G, Allais G, Castagnoli Gabellari I, et al. Almotriptan for menstrually related migraine. Expert Opin Pharmacother. 2011;12:1933–1943.
   PubMed Web of Science ®Google Scholar
• Casolla B, Lionetto L, Candela S, et al. Treatment of perimenstrual migraine with triptans: an update. Curr Pain Headache Rep. 2012;16(5):445–451.
   PubMed Web of Science ®Google Scholar
• Diamond ML, Cady RK, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and non-menstrually related migraines. Headache. 2008;48:248–258.
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006;27:193–197.
   PubMed Web of Science ®Google Scholar
• Bartolini M, Giamberardino MA, Lisotto C, et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012;13:401–406.
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, D’Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011;31(2):144–151.
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Benedetto C, et al. Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci. 2010;31(Suppl 1):S115–S119.
   PubMedGoogle Scholar
• Cassano D, Pizza V, Busillo V. Almotriptan in the acute treatment of Vestibular migraine: a retrospective study. J Headache Pain. 2015 Dec;16(Suppl 1):A114.
   PubMedGoogle Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache. 2001;41(5):449–455.
   PubMed Web of Science ®Google Scholar
• Jannsen Pharmaceuticals Inc. AXERT® (almotriptan malate) tablets: prescribing information. [last accessed May 2017.]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf
   Google Scholar
• Thorlund K, Toor K, Wu P, et al. Comparative tolerability of treatments for acute migraine: A network meta-analysis. Cephalalgia. 2017;37(10):965–978.
   PubMed Web of Science ®Google Scholar
• Hens M, Villaverde-Hueso A, Alonso V, et al. Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries. Eur J Health Econ. 2014;15(4):433–437.
   PubMed Web of Science ®Google Scholar
• Slof J. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the ‘Act when Mild’ study. Appl Health Econ Health Policy. 2012;10(3):201–215.
   PubMedGoogle Scholar
• Almogram SMPC. Available at: https://www.medicines.org.uk/emc/product/6579/smpc [last accessed Feb 2019.]
   Google Scholar
• Spielmann K, Kayser A, Beck E, et al. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia. 2018;38(6):1081–1092.
   PubMed Web of Science ®Google Scholar
• Harris GE, Wood M, Ystrom E, et al. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: follow-up from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol. 2018;32(3):247–255.
   PubMed Web of Science ®Google Scholar
• Duong S, Bozzo P, Nordeng H, et al. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010;56(6):537–539.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. .
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018 Feb 1;19(1):10. .
   PubMed Web of Science ®Google Scholar
• Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11(2):175–177.
   PubMed Web of Science ®Google Scholar
• British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache, medication-overuse headache. 2010. 3rd edn. Available from: http://www.bash.org.uk/guidelines
   Google Scholar
• Viana M, Genazzani AA, Terrazzino S, et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891–896.
   PubMed Web of Science ®Google Scholar
• Capi M, Gentile G, Lionetto L, et al. Pharmacogenetic considerations for migraine therapies. Expert Opin Drug Metab Toxicol. 2018;14:1161–1167.
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, D’Alonzo L, et al. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2013;9(5):637–644.
   PubMed Web of Science ®Google Scholar
• Kassem AA. Formulation approaches of triptans for management of migraine. Curr Drug Deliv. 2016;13(6):882–898.
   PubMed Web of Science ®Google Scholar
• Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018;11:2221–2227.
   PubMed Web of Science ®Google Scholar
• Tepper SJ. Anti-calcitonin gene-related peptide (cgrp) therapies: update on a previous review after the american headache society 60th scientific meeting, San Francisco, June 2018. Headache. 2018;58(Suppl 3):276–290.
   PubMedGoogle Scholar
• Pascual J. Efficacy of BMS-927711 and other gepants vs triptans: there seem to be other players besides CGRP. Cephalalgia. 2014;34(12):1028–1029.
   PubMed Web of Science ®Google Scholar